Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.83, representing a -1.87% change from its previous close.
Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $7.21, representing a -1.77% change from its previous close.
Sensus Healthcare (SRTS) Surges 7.9%: Is This an Indication of Further Gains?
Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day.
Wall Street Bulls Look Optimistic About Sensus Healthcare (SRTS): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 36.01%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Wall Street Analysts See a 39.66% Upside in Sensus Healthcare (SRTS): Can the Stock Really Move This High?
The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes Sensus Healthcare (SRTS) a Good Fit for 'Trend Investing'
Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Sensus Healthcare: Q3 Results Showed That The Stock Is Undervalued
Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal movement, presenting a potential 150% upside over the next five years under my assumptions.
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (SRTS) Surpasses Q3 Earnings and Revenue Estimates
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.09 per share a year ago.
